Events Archives - Page 35 of 128

3 minute read

Scholar Rock To Present Clinical And Biomarker Data From The Phase 1 DRAGON Trial At The SITC 38th Annual Meeting

October 19, 8:18 AM

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181Scholar Rock (NASDAQ:SRRK), a Phase 3 clinical-stage

SRRK

2 minute read

Meet Entrepreneur, Crypto Expert Carlos Vivas At Benzinga’s Future Of Digital Assets Event

By Murtuza Merchant

October 18, 9:30 AM

Carlos Vivas, director and senior principal engineer at The Depository Trust & Clearing Corporation (DTCC), is recognized for his contributions to the world of technology and finance.

ETH

1 minute read

RAPT Therapeutics Announces Two FLX475 Presentations At The Society For Immunotherapy Of Cancer 2023 Annual Meeting

By Benzinga Newsdesk

October 18, 9:11 AM

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet

RAPT

2 minute read

Evoke Pharma’s Abstract Entitled “Superiority Of Nasal Spray Compared To Orally Administered Metoclopramide In Reducing Healthcare Costs In Treating Diabetic Gastroparesis Patients” To Be Presented At The American College Of Gastroenterology 2023

By Benzinga Newsdesk

October 18, 8:36 AM

Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its

EVOK

3 minute read

CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar For Primary Biliary Cholangitis To Be Featured In An Oral Late-Breaking Presentation At The Liver Meeting 2023

By Benzinga Newsdesk

October 18, 8:13 AM

Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th Fifth oral late-breaking presentation of seladelpar results at The Liver Meeting®NEWARK, Calif.,

CBAY

2 minute read

Mirum Pharmaceuticals Announces New PDUFA Date Of March 13, 2024 For LIVMARLI For The Treatment Of Cholestatic Pruritus In Progressive Familial Intrahepatic Cholestasis

By Benzinga Newsdesk

October 17, 4:37 PM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral

MIRM

1 minute read

ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC 114 In EGFR/HER2 Exon 20 Mutated NSCLC At The European Society Of Medical Oncology Congress 2023

By Benzinga Newsdesk

October 17, 4:30 PM

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster

ORIC

3 minute read

Data From Two Studies Demonstrating Financial Impact Of INPEFA To Be Presented At The Academy Of Managed Care Pharmacy Nexus 2023 National Meeting

By Benzinga Newsdesk

October 17, 4:03 PM

Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failureTHE WOODLANDS,

LXRX

4 minute read

Rhythm Pharmaceuticals Presents Data From Its Long-term Extension Study Of Setmelanotide Showing Sustained And Deepened BMI Reduction In Patients With Hypothalamic Obesity At One Year At ObesityWeek 2023

By Benzinga Newsdesk

October 17, 4:02 PM

-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one

RYTM

2 minute read

Arcus Biosciences To Present Data From Ongoing EDGE-Gastric Study At ASCO Plenary And To Report Q3 Financial Results On November 7

By Benzinga Newsdesk

October 17, 4:01 PM

Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line upper gastrointestinal cancers will be presented at the virtual ASCO Monthly Plenary

RCUS